Valuation
- Market cap
- 507,925,000
- Revenue TTM
- $297,180,000
- Net income TTM
- $-51,640,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -17.38%
- Debt to equity
- -5.07
Trading
- Volume
- 2,070,800
- Avg volume
- 939,138
- Day's range
- $6.91 – $7.72
- Shares out
- 66,050,000
- Stochastic %K
- 14%
- Beta
- 1.34
- Analysts
- Strong Sell
- Price target
- $15.75
Company profile
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes vario...
Show more
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 949 284 4555
- Website
- https://www.evolus.com
- Address
- 520 Newport Center Drive, Suite 1200, Newport Beach, United States
Latest news
No headlines yet.
